NFKB1 and prostate cancer: While it has been recently reported by us that melatonin can inhibit the constitutively active NF-κB via membrane G protein-coupled MT1 receptor in LNCaP and 22Rv1 prostate cancer cells [23], we would like to confirm that the MT1 receptor is responsible for mediating the inhibitory effect of melatonin on AR-V7 induced NF-κB activation observed in the present investigation.